Someone you love is considering — or has already started — psychedelic-assisted therapy. You are a spouse, partner, parent, adult child, sibling, or close friend, and you have questions: Is this safe? Is this legitimate? Is it approved? What's the evidence for their condition? How do I support them? What if it doesn't work? What if they have a difficult experience? This guide is written for you. It is not a replacement for the patient's clinical care — your loved one's psychiatrist, family physician, and a licensed clinical team are the people making the medical decisions. But the support of family and loved ones is part of the care system, and the more accurate your understanding of what psychedelic-assisted therapy is and isn't, the better positioned you are to be useful. This article covers Canadian regulatory status, the evidence base, practical support across preparation/dosing/integration, what not to do, when to call crisis resources, and how to look after your own mental health while supporting someone else's.

If your loved one is in crisis right now

9-8-8 Suicide Crisis Helpline — call or text 9-8-8 (Canada-wide, 24/7)

Talk Suicide Canada — 1-833-456-4566 (24/7) or text 45645 (4 PM–midnight ET)

In Quebec: 1-866-APPELLE (1-866-277-3553)

Kids Help Phone (under 30) — 1-800-668-6868 or text CONNECT to 686868

In imminent danger: call 911 or take your loved one to the nearest emergency department

Key takeaways

Psychedelic-assisted therapy in Canada is real, regulated, and partly evidence-based — Spravato (esketamine) is Health Canada-approved for treatment-resistant depression; off-label ketamine has RCT support; psilocybin and MDMA are accessed under the Special Access Program (SAP) and are investigational.

Family/loved ones are part of the support system, not the clinical team — your role is supportive, not interpretive or directive.

Practical day-of support matters: transport to and from sessions is often necessary; the 24-hour no-driving rule after dissociative or psychedelic dosing means your loved one cannot drive themselves home.

You typically cannot be in the dosing room for adult patients in non-dyadic formats; the dosing space is patient-and-therapist (or patient-and-clinician dyad).

Couples/dyadic formats exist for specific indications and are different (see related cluster).

What not to do: don't interpret their experience for them, don't pressure for outcomes, don't demand session details.

Caregiver burden is real — supporting someone through mental illness is hard; your own mental health matters.

Honest framing: psychedelic-assisted therapy may help, may produce partial response, may not respond. It is part of ongoing care, not a one-shot fix.

End-of-life distress context: if your loved one has cancer or life-limiting illness and is exploring psilocybin SAP, the family role is particularly meaningful — coordination with palliative care matters.

Who this guide is for

This article is written for the people who love someone considering or undergoing psychedelic-assisted therapy. That includes:

Spouses and partners — often the closest day-to-day witnesses; frequently the people coordinating transport and post-session presence
Parents — supporting an adult child considering psychedelic-assisted therapy, including young adults and adult children with serious mental illness
Adult children — supporting an aging parent, particularly in end-of-life distress contexts
Siblings — sometimes the first person told; sometimes the long-distance support
Close friends — chosen family; often the practical support when biological family is absent or strained

You are not the patient. You are not the clinician. But you are part of the picture, and the patient's care team will often welcome your appropriate involvement.

Is this safe? Is this legitimate?

These are the right first questions. The honest answer:

Spravato (esketamine) is Health Canada-approved for treatment-resistant depression (TRD), as of May 2020. It is delivered in REMS-style supervised settings (patient self-administers nasal spray with monitoring; ~2-hour observation post-dose). This is a fully regulated, on-label medication.
Ketamine for psychiatric use is off-label. Ketamine itself is Health Canada-approved (for anaesthetic use); the off-label psychiatric use is supported by RCT evidence (notably Anand 2023 ELEKT-D — NEJM, ketamine non-inferior to ECT in non-psychotic TRD) and by long-standing clinical practice in specialty psychiatric settings. Off-label is not the same as illegitimate; it means the regulator has not approved that specific indication, but the medication is available for clinicians to prescribe at their judgment.
Psilocybin is a Schedule III controlled substance in Canada. Legal access is via the Special Access Program (SAP), with case-by-case Health Canada authorization for end-of-life distress and (less commonly) treatment-resistant depression after conventional treatments have failed. Each application is reviewed individually; psilocybin is not generally available outside SAP, clinical trials, or the rare Section 56 exemptions.
MDMA is a Schedule I controlled substance. Access is via SAP and clinical trials only. MDMA-assisted therapy received a CRL (complete response letter) from the FDA in August 2024 — Lykos's resubmission and Health Canada's eventual posture remain in development. As of 2026, MDMA in Canada is investigational under SAP and trial settings.

Legitimate, regulated, supervised psychedelic-assisted therapy in Canada exists. It is delivered in licensed clinics, hospital programs, and SAP-authorized settings. It is not the same as recreational use, retreat tourism, or unsupervised self-administration. If your loved one is being offered care at a credentialed clinic with physician oversight, that is a meaningfully different situation from underground or unregulated contexts.

What's the evidence for [their condition]?

The evidence base varies substantially by condition. The honest picture:

Treatment-resistant depression (TRD): strongest evidence base. Spravato has Phase 3 program data (TRANSFORM-1/2/3, SUSTAIN-1/2). Off-label ketamine has Anand 2023 ELEKT-D non-inferiority to ECT, plus a substantial pre-2023 literature. Psilocybin for TRD has Goodwin 2022 (NEJM; single-dose psilocybin showed response over 3 weeks) and Carhart-Harris 2021 (NEJM; psilocybin vs escitalopram, no significant difference on primary endpoint).
PTSD: MDMA-assisted therapy has Mitchell 2021/2023 (MAPP1/MAPP2; Nature Medicine) — Phase 3 trials with significant improvement vs placebo+therapy. The August 2024 FDA CRL added complexity to the regulatory pathway. Ketamine for PTSD has smaller RCT base (Feder 2014, 2021).
End-of-life distress / cancer-related anxiety and depression: psilocybin has Griffiths 2016 and Ross 2016 (Johns Hopkins and NYU; Journal of Psychopharmacology) — both showed substantial decreases in depression and anxiety sustained at 6-month follow-up. This is the strongest single-substance, single-indication evidence base in the field.
Treatment-resistant anxiety, OCD, AUD, eating disorders, chronic pain: smaller RCT base; growing literature; SAP applications considered case-by-case.
Suicidality: ketamine has rapid anti-suicidal effect signals (Wilkinson 2018 meta-analysis; Murrough 2015). Spravato product label mentions reduction in depressive symptoms in patients with active suicidal ideation (ASPIRE-1/2).

For substance-specific depth, see Treatment-Resistant Depression and Psychedelic-Assisted Therapy, PTSD and Psychedelic-Assisted Therapy, End-of-Life Distress and Psychedelic-Assisted Therapy, Suicidality and Psychedelic-Assisted Therapy.

The evidence does not say "psychedelic-assisted therapy will fix them." It says: for specific conditions, in supervised settings, with preparation and integration, a meaningful proportion of patients show improvement; some do not respond; some show partial response; durability varies and follow-up care is part of the picture.

How psychedelic-assisted therapy is typically structured

Understanding the structure helps you support your loved one. Most protocols include:

Intake and screening — medical history, medications, mental health history, capacity to consent, suitability assessment. Some patients are screened out at this stage; that is appropriate clinical practice, not a personal failure.
Preparation phase — typically several sessions with the therapist before the first dosing day. Builds rapport, sets intention, reviews what to expect, identifies challenges.
Dosing day(s) — the medication session itself. Length varies: ketamine ~1–2 hours of dissociative effects plus monitoring; Spravato ~2 hours observation; psilocybin ~6–8 hours; MDMA ~6–8 hours.
Integration phase — sessions in the days and weeks after dosing to make sense of the experience and translate it into ongoing change.
Maintenance / follow-up — ongoing care, including continuation of antidepressant medications, ongoing psychotherapy, lifestyle factors.

For more detail, see Preparation Phase, What to Expect at Your First Session, Integration Phase.

Practical support — what you can actually do

Before the dosing day

Logistics: help with appointment scheduling, paperwork, insurance prior auth navigation
Day-of planning: confirm transport plan; arrange a quiet, low-demand environment for the 24–48 hours after
Emotional support: pre-session anxiety is common; presence and listening are useful; reassurance about safety is appropriate (the setting is supervised)
Don't: don't pressure them about what they "should" experience; don't predict outcomes; don't impose your own beliefs about what the medicine does

Day of the dosing session

Drive them in: they should not drive themselves to the session if they are anxious enough to want a ride; in any case they will not be able to drive themselves home
Wait or return: most clinics will tell you whether to wait on-site or return at a specific time; ask in advance
Drive them home: this is the practical core. The 24-hour no-driving rule after dissociative or psychedelic dosing applies to ketamine, esketamine, psilocybin, and MDMA. Your loved one will not be in a state to drive themselves, ride a bike, or operate machinery for at least 24 hours.
Keep the post-session environment calm: low-stimulation home; meals ready; phones quiet; minimal demands

Can I be in the room with them during dosing?

For most adult patients in standard (non-dyadic) protocols: no. The dosing space is the patient and the trained therapist (or therapist dyad). This is a clinical setting, not a family setting, and the patient's interior process needs to unfold without family-system dynamics layered on top. This is not a rejection of you; it is the structure of the work.

Exceptions and adjacent formats:

Couples/dyadic psychedelic-assisted therapy — both partners are patients, and the work is explicitly couples therapy. This is a different protocol with different indications. See Couples and Dyadic Psychedelic-Assisted Therapy.
End-of-life distress with family presence — in some palliative-care-coordinated psilocybin SAP cases, family presence at parts of the session may be considered. This is decided clinically, case by case.
Pediatric / capacity-limited contexts — generally outside the scope of current Canadian psychedelic-assisted therapy; SAP applications for minors are uncommon.

After the session — the first 24–48 hours

Stay accessible — you don't need to hover, but be reachable
Drive them home and don't expect them to drive for 24 hours
Quiet environment — many people are tired, emotionally raw, or processing
Light food and hydration
Don't push for a download — let them talk if they want to; don't interrogate
Watch for warning signs — persistent suicidal thinking, prolonged dissociation, severe anxiety, sleep disruption beyond 48 hours; if present, call the clinic; if acute, use the crisis resources at the top of this page or call 911

Integration phase — the weeks after

Ongoing emotional support — integration is where the experience becomes durable change, and that takes weeks
Respect the therapy relationship — your loved one's integration sessions are with their therapist; you are adjacent, not central
Notice patterns — new behaviours, new patterns; share observations with your loved one if they're useful, but without prescription
Be patient with non-response or partial response — this is part of the work

For more detail, see Integration Phase of Psychedelic-Assisted Therapy.

What family/loved ones should NOT do

Don't interpret the experience for the patient — psychedelic and dissociative experiences are autobiographical to the person who had them. Your interpretation is your interpretation. Let theirs be theirs.
Don't pressure for outcomes — "do you feel better yet?" repeated daily produces pressure, not improvement
Don't demand session details — they may share, they may not; either is fine
Don't impose your spiritual / metaphysical framework — let them describe their experience in their own terms
Don't compare to other people's stories — your friend's cousin's experience is not a rubric
Don't second-guess the clinical team — if you have legitimate concerns, raise them through the patient (with their consent) or through formal channels
Don't undermine their existing treatment — if they're on antidepressants, that is between them and their psychiatrist
Don't broadcast — the patient's mental health information is theirs, not yours, to share

How does psychedelic-assisted therapy fit with their existing care?

It is almost never a replacement for ongoing care. Most patients receiving psychedelic-assisted therapy:

Continue (or thoughtfully taper) existing antidepressants under psychiatrist supervision — psilocybin and MDMA generally require SSRI taper; ketamine and esketamine are often compatible with SSRIs
Continue ongoing psychotherapy with their primary therapist — this is the integration backbone
Maintain primary care relationships
Are coordinated through coordinated care model, which works alongside (not instead of) the existing care team

For ATMA CENA's coordination framework, see how ATMA CENA coordinates care.

What if they have a difficult experience?

Difficult experiences happen. They are not the same as treatment failure. In supervised settings:

Therapists are trained to navigate difficult passages — anxiety, fear, grief, intense emotion are part of the territory
Difficult experiences often integrate into meaningful change — the literature uses the term "challenging experiences" rather than "bad trips" specifically because the framing matters
Adverse events are tracked and reported — clinics have protocols
Persistent post-session distress (more than 48–72 hours) warrants clinical contact; the clinic has after-hours protocols

If your loved one comes home distressed:

Stay calm and present
Don't push for explanation
Hydration, food, rest, low stimulation
Call the clinic if distress is severe or persistent
Use crisis resources if they express suicidal intent or you assess imminent risk

What if they don't respond?

This is real and it is not a personal failure. Treatment-resistant conditions have multiple potential pathways. Non-response or partial response to psychedelic-assisted therapy means:

The patient and clinical team will discuss next steps
Other modalities (different medication classes, ECT, rTMS, intensive psychotherapy formats) remain on the table
Some patients respond to a different psychedelic medicine than the one initially trialled
Re-dosing protocols exist for some indications (Spravato has explicit maintenance dosing; psilocybin SAP applications can be re-submitted)

Family role: don't catastrophize, don't blame the patient, don't blame yourself, and don't blame the clinic. The honest framing of psychedelic-assisted therapy is that it helps a meaningful proportion of patients with specific conditions; it does not help everyone.

End-of-life distress context — supporting a loved one with life-limiting illness

If your loved one has cancer or another life-limiting illness and is considering psilocybin under SAP for end-of-life distress, your role is particularly meaningful:

Coordinate with palliative care — SAP psilocybin for end-of-life distress is most appropriately integrated with the palliative team
Practical caregiving overlap — you may already be the primary caregiver; the dosing day adds logistics
Family presence considerations — in some end-of-life distress cases, family presence at parts of the protocol is appropriate, decided clinically
Advance care planning — the broader conversation is part of the picture
Your own grief and anticipatory loss — supporting someone with terminal illness is profound work; your mental health is part of the picture

For more detail, see End-of-Life Distress and Psychedelic-Assisted Therapy.

When you are also the primary caregiver — couples/dyadic considerations

If you are the patient's primary caregiver — particularly in long-term illness, disability, or chronic mental illness — your relationship with the patient is itself part of the clinical picture. Couples and dyadic psychedelic-assisted therapy formats exist for specific indications (relational distress, couples processing trauma, PTSD with attachment/relational dimensions). This is different from supporting your partner through individual psychedelic-assisted therapy. If your situation is one where the relationship itself is part of what is suffering, dyadic formats may be relevant to discuss with the clinical team.

For more detail, see Couples and Dyadic Psychedelic-Assisted Therapy.

Caregiver self-care — your mental health matters

Caregiver burden is real and well-documented. Supporting someone with treatment-resistant depression, PTSD, end-of-life distress, or other serious mental health conditions is hard work, and it accumulates. You are not selfish for needing your own support.

Your own therapist — many family members of patients in serious mental health treatment benefit from their own therapy
CMHA (Canadian Mental Health Association) branches across provinces offer family education, support groups, and counselling — CMHA Ontario, CMHA BC, CMHA Alberta, and provincial equivalents
Provincial caregiver support — many provinces have caregiver-specific resources (Ontario Caregiver Organization, Caregivers Alberta, Family Caregivers of BC)
Peer support groups — both general (NAMI-style; Canadian equivalents through CMHA and Mood Disorders Society of Canada) and condition-specific
Bereavement support — for end-of-life distress contexts, bereavement counselling before and after death is appropriate

If you are in distress yourself: the 9-8-8 line is for you too. Talk Suicide Canada (1-833-456-4566) takes calls from family members. You don't have to be the one in crisis to call.

Frequently asked questions

Is psychedelic-assisted therapy approved in Canada? Spravato (esketamine) is Health Canada-approved for treatment-resistant depression. Off-label ketamine is widely used in psychiatric practice. Psilocybin and MDMA are accessed via the Special Access Program (SAP) and are investigational.

Will it fix them? Honest answer: it may help, may produce partial response, may not respond. It is part of ongoing care, not a one-shot fix. The evidence supports meaningful improvement for a meaningful proportion of patients with specific conditions in supervised settings.

Can I sit in on the dosing session? For most adult patients in standard formats: no. The dosing space is patient and trained therapist. Exceptions include couples/dyadic formats, some end-of-life distress contexts, and other clinically-decided situations.

Can I drive them home? Yes — and you should plan to. The 24-hour no-driving rule applies to all dissociative and psychedelic dosing.

Should I ask them about their experience? Be available; don't interrogate. Let them lead. If they don't share, that is their right. The integration work happens with their therapist.

What if they have a difficult experience? Stay calm, stay present, low stimulation, hydration, contact the clinic if distress is severe. Difficult experiences are not the same as treatment failure.

What if they don't respond? Non-response is part of the picture for treatment-resistant conditions. The clinical team will discuss next steps. Don't catastrophize, don't blame.

Will they need ongoing therapy after? Yes — almost always. Integration is the work that translates the dosing experience into durable change. This is part of the protocol, not an extra.

What if they're suicidal? Use the crisis resources at the top of this page. 9-8-8 call/text, Talk Suicide Canada 1-833-456-4566, or 911 for imminent danger. See also Suicidality and Psychedelic-Assisted Therapy.

What about spirituality/religion? Patient-led. Don't impose your framework. Their experience is theirs to interpret, with their therapist.

Will my insurance cover this? Spravato has the most established coverage pathways (PSHCP, Manulife, Sun Life, Green Shield with prior auth). Ketamine is dominantly out-of-pocket with VAC and public hospital exceptions. Psilocybin SAP is dominantly out-of-pocket with the Quebec RAMQ Farzin/Stephan precedent and Filament no-charge supply as exceptions.

What if I'm worried about the clinic itself? Verify credentials (provincial physician college, regulated psychotherapist licensure), ask about supervision protocols, ask about complaint pathways. A reputable Canadian clinic will answer these questions transparently.

How ATMA CENA works with families

Information call: family members welcome with patient consent
Preparation phase: family/caregiver coordination as appropriate
Dosing day logistics: transport coordination is supported; family presence in the dosing space is generally not part of standard protocols (with the exceptions described above)
Integration phase: family role is supportive, with clinical care led by the integration therapist
Coordinated care: ATMA CENA works alongside the patient's existing primary care, psychiatrist, and therapist
Referral to family support resources: when caregiver burden is significant, ATMA CENA can route to appropriate family support services

What this guide does NOT do

It does not interpret your loved one's specific situation — that is the clinical team's role
It does not tell you what to expect for your loved one's specific condition with certainty — outcomes vary
It does not replace your loved one's clinical care
It does not authorize you to make decisions for them — capacitous adults make their own treatment decisions
It does not replace your own therapy if you need it

Sources

Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
Anand A, Mathew SJ, Sanacora G, et al. (2023). Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal of Medicine, 388(25):2315-2325. PMID: 37224135.
Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6):1025-1033. PMID: 33972795.
Mitchell JM, Ot'alora G M, van der Kolk B, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine, 29(10):2473-2480. PMID: 37709999.
Griffiths RR, Johnson MW, Carducci MA, et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. Journal of Psychopharmacology, 30(12):1181-1197. PMID: 27909164.
Ross S, Bossis A, Guss J, et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer. Journal of Psychopharmacology, 30(12):1165-1180. PMID: 27909165.
Health Canada — Spravato Product Monograph: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
Health Canada — Special Access Program: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access.html
9-8-8 Suicide Crisis Helpline (Canada): https://988.ca/
Talk Suicide Canada: https://talksuicide.ca/
Canadian Mental Health Association (CMHA) — National: https://cmha.ca/
Mood Disorders Society of Canada — Family resources: https://mdsc.ca/

Older Adults and Psychedelic-Assisted Therapy — supporting an aging parent
Couples and Dyadic Psychedelic-Assisted Therapy — when the relationship itself is the work
End-of-Life Distress and Psychedelic-Assisted Therapy — supporting a loved one with life-limiting illness
Preparation Phase of Psychedelic-Assisted Therapy
Integration Phase of Psychedelic-Assisted Therapy
What to Expect at Your First Session
How ATMA CENA coordinates care
Suicidality and Psychedelic-Assisted Therapy

Last updated: 2026-05-06

For Family Members and Loved Ones — A Canadian Guide to Psychedelic-Assisted Therapy